Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Kiniksa Pharmaceuticals International Q3 2026 Results: Net Income $47.3M, Up 156.8% YoY

Kiniksa Pharmaceuticals reported total product revenue of $285.97 million for the third quarter of 2026, a significant increase from $180.86 million in the prior year. Net income for the quarter rose to $47.35 million, while the company maintained a strong liquidity position with $568.76 million in cash, cash equivalents, and short-term investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue286.0180.9
Profit before tax59.127.2
Net income47.318.4
EPS (diluted, $ a share)$0.56$0.23

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+156.8%
Revenue, year on year+58.1%
Operating margin19.0%
Source

10-Q filed with the SEC, NASDAQ: KNSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Kiniksa Pharmaceuticals International, plc: key numbers

Share price
$95.11Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Kiniksa Pharmaceuticals International, plc

All →
4:34 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $1.11M of Stock

Michael R. Megna, CAO, sold 11,280 shares of Kiniksa Pharmaceuticals International, plc at $98.54 a share, worth $1.11M in total on Nov 9, 2026. Shares held after the trade: 12,697 (-47.0%).

Value
$1.11M
Shares
11,280
Price
$98.54
Role
CAO
Holding change
-47.0%
Trade date
Nov 9, 2026
4:52 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $14.3M of Stock

Sanj K. Patel, Chairman & CEO, sold 151,300 shares of Kiniksa Pharmaceuticals International, plc at $92.35 to $96.05 a share (average $94.71) in 5 transactions, worth $14.3M in total on Nov 4, 2026. Shares held after the trade: 774,500 (-3.4%).

Value
$14.3M
Shares
151,300
Average price
$94.71
Role
Chairman & CEO
Holding change
-3.4%
Trade date
Nov 4, 2026
7:30 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International Chairman & CEO Sanj K. Patel Sells $37.4M of Stock

Sanj K. Patel, Chairman & CEO, sold 402,394 shares of Kiniksa Pharmaceuticals International, plc at $90.77 to $98.16 a share (average $92.92) in 14 transactions, worth $37.4M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 780,037 (-0.6%).

Value
$37.4M
Shares
402,394
Average price
$92.92
Role
Chairman & CEO
Holding change
-0.6%
Trade date
Oct 30, 2026 to Nov 3, 2026
6:33 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CFO Mark Ragosa Sells $3.39M of Stock

Mark Ragosa, CFO, sold 36,783 shares of Kiniksa Pharmaceuticals International, plc at $91.40 to $94.01 a share (average $92.16) in 4 transactions, worth $3.39M in total on Nov 2, 2026. Shares held after the trade: 20,854 (-1.0%).

Value
$3.39M
Shares
36,783
Average price
$92.16
Role
CFO
Holding change
-1.0%
Trade date
Nov 2, 2026
6:29 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International CMO John F. Paolini Sells $8.94M of Stock

John F. Paolini, CMO, sold 96,000 shares of Kiniksa Pharmaceuticals International, plc at $92.02 to $97.77 a share (average $93.09) in 10 transactions, worth $8.94M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 69,922 (-1.0%).

Value
$8.94M
Shares
96,000
Average price
$93.09
Role
CMO
Holding change
-1.0%
Trade date
Oct 30, 2026 to Nov 2, 2026
6:27 PM ET Form 4
Insider Selling

Kiniksa Pharmaceuticals International COO Ross Moat Sells $9.63M of Stock

Ross Moat, COO, sold 103,585 shares of Kiniksa Pharmaceuticals International, plc at $91.23 to $97.76 a share (average $92.93) in 11 transactions, worth $9.63M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 10,294 (-6.6%).

Value
$9.63M
Shares
103,585
Average price
$92.93
Role
COO
Holding change
-6.6%
Trade date
Oct 30, 2026 to Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.